News

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic…

1 year ago

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK…

1 year ago

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a…

1 year ago

Aveanna Announces Second Quarter 2024 Earnings Release Date and Conference Call

ATLANTA, July 18, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will…

1 year ago

Teleflex Announces Second Quarter 2024 Earnings Conference Call Information

WAYNE, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second…

1 year ago

Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder

Topline results are expected in Q3 2025 ADELAIDE, Australia and CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq:…

1 year ago

Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine

EMA will now initiate its centralized review procedure under accelerated assessment for Bavarian Nordic’s chikungunya vaccine COPENHAGEN, Denmark, July 18,…

1 year ago

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Boehringer_Workplace_Lab_Research Media image Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncologyFurther data read-outs expected in 2024 in oncology,…

1 year ago

Inventiva announces a €20.1 million issuance of royalty certificates

Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng).Royalty of 3% on future net…

1 year ago

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

PluriCDMO™, the Company’s contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production…

1 year ago